Healthcare >> CEO Interviews >> October 5, 2000
DR. ASHLEY LAWTON, President of Phylos, joined the company in August
1997. He was previously Vice President, Operations at Genzyme
Corporation. Prior to his tenure with Genzyme, he served as Executive
Vice President and General Manager of Repligen Corporation and held
senior management positions with Celltech Biologics and Eli Lilly & Co.
Ltd. He has an established track record in managing biotechnology
operations, negotiating deals involving technology licensing and
contract services, and developing protein biopharmaceuticals. Dr. Lawton
received his PhD in Biochemistry from Southampton University, UK. He is
also a graduate of the Executive MBA Program of Boston University. Profile
Dr. Lawton: The company was founded in mid-1997 to exploit an in-vitro
combinatorial biology technology, which we call the
